Schering-Plough CEO extra careful of cholesterol-drug pipeline

11/14/2007 | Reuters

Schering-Plough Corp. has been cautious in developing drugs to raise "good" HDL cholesterol levels, even as other cholesterol treatments such as Vytorin, developed by the company with Merck & Co., have been deemed the world's top-selling prescription drugs. "If there's a way we can probe the area and prove to ourselves that it's a safe approach, then we will go after it," CEO Fred Hassan said, noting the problems encountered by Pfizer in testing its CETP inhibitor torcetrapib.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX